Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.

Article Details

Citation

Copy to clipboard

Debnath AK

Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase.

J Med Chem. 2002 Jan 3;45(1):41-53.

PubMed ID

11754578 [ View in PubMed

]

Abstract

Pharmacophore hypotheses were developed for a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex (MAC) and human dihydrofolate reductase (hDHFR). Training sets consisting of 20 inhibitors were selected in each case on the basis of the information content of the structures and activity data as required by the HypoGen program in the Catalyst software. In the case of MAC DHFR inhibitors, the best pharmacophore in terms of statistics and predictive value consisted of four features: two hydrogen bond acceptors (HA), one hydrophobic (HY) feature, and one ring aromatic (RA) feature. The selected pharmacophore hypothesis yielded an rms deviation of 0.730 and a correlation coefficient of 0.967 with a cost difference (null cost minus total cost) of approximately 52. The pharmacophore was validated on a large set of test inhibitors. For the test series, a classification scheme was used to distinguish highly active from moderately active and inactive compounds on the basis of activity ranges. This classification scheme is more practical than actual estimated values because these values have no meaning for compounds yet to be tested except that they indicate whether the compounds will be active or inactive in a biological assay. For the training set, the success rate for predicting active and inactive compounds was 100%. For the test set, the success rate in predicting active compounds was greater than 92% while about 7% of the inactive compounds were predicted to be active. This successful prediction was further validated on three structurally diverse compounds active against MAC DHFR. Two compounds mapped well onto three of the four features of the pharmacophore. The third compound was mapped to all four features of the pharmacophore. This validation study provided confidence for the usefulness of the selected pharmacophore model to identify compounds with diverse structures from a database search. Comparison of pharmacophores for inhibitors of human and MAC DHFR is expected to reveal fundamental differences between these two pharmacophores that may be effectively exploited to identify and design compounds with high selectivity for MAC DHFR.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Sri-9439	Dihydrofolate reductase	IC 50 (nM)	4.3	N/A	N/A	Details
Sri-9439	Dihydrofolate reductase	IC 50 (nM)	0.98	N/A	N/A	Details